FindTrial
Sign In

Study on the mechanism of ISCU driving cisplatin resistance via exosomes regulating ferroptosis and mTOR pathway in non-small cell lung cancer

Study on the mechanism of ISCU driving cisplatin resistance via exosomes regulating ferroptosis and mTOR pathway in non-small cell lung cancer

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500100573
Enrollment
Unknown
Registered
2025-04-11
Start date
2024-06-30
Completion date
Unknown
Last updated
2025-04-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

lung adenocarcinoma and lung squamous cell carcinoma

Interventions

Trial group:NA

Sponsors

Hunan Provincial People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1.lung adenocarcinoma; 2.lung squamous cell carcinoma;

Exclusion criteria

Exclusion criteria: Lung cancer patients who have undergone radiotherapy and chemotherapy.

Design outcomes

Primary

MeasureTime frame
ISCU;eIF4E2;4E-BP3;—

Countries

China

Contacts

Public ContactSile Liu

Hunan Provincial People's Hospital

liusile@hunnu.edu.cn+86 731 84762779

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026